Public comment period · §3
Draft monograph: Tesamorelin — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-TESAMORELIN-/001 | Dr Zdenka Nyquist-Obiora | The document should state what a reader ought to do | Not accepted |
| DRAFT-TESAMORELIN-/002 | Dr Marisol Dunmore-Ekpo | Trials are described as terminated where they completed as planned | Accepted in part |
| DRAFT-TESAMORELIN-/003 | Dr Eamon Immelmann | The monograph does not tell a reader that a stated mass may be substantially counter-ion and water | Accepted |
| DRAFT-TESAMORELIN-/004 | Vittoria Ylönen | The monograph should not describe how the compound is supplied outside a regulated route | Noted, no amendment |
| DRAFT-TESAMORELIN-/005 | Dr Vasilisa Immelmann | Regulatory status is stated without naming the jurisdiction | Accepted |
| DRAFT-TESAMORELIN-/006 | Dr Ndidi Ravensworth-Ilunga | Every contributing trial shares one sponsor and the monograph does not say so | Accepted |
| DRAFT-TESAMORELIN-/007 | Dr Piotr Hollingworth | The mechanism section is written with more confidence than the clinical section it precedes | Accepted in part |
| DRAFT-TESAMORELIN-/008 | Dr Nadezhda Lavrentiev | The difference between pulsatile and continuous administration is not addressed | Accepted |
| DRAFT-TESAMORELIN-/009 | Dr Vasilisa Sandringham-Adu | Declared interests should appear on the document rather than on a separate page | Noted, no amendment |
| DRAFT-TESAMORELIN-/010 | Ivo Mountstephen | The search date is not on the face of the document | Accepted |
| DRAFT-TESAMORELIN-/011 | Dr Liesbeth Nyquist-Obiora | Storage and reconstitution guidance is given without stating what it rests on | Accepted in part |
| DRAFT-TESAMORELIN-/012 | Dr Liesbeth Nordhagen industry | The document should not describe uses outside the approved indication | Not accepted |
| DRAFT-TESAMORELIN-/013 | Dr Melisande Thorsby-Nakamura | The analytical section assumes a reference standard that is not generally available | Accepted |
| DRAFT-TESAMORELIN-/014 | Dr Leonhard Quenneville | The analytical section is longer than the clinical assessment it accompanies | Accepted in part |
| DRAFT-TESAMORELIN-/015 | Dr Lorcan Zaleski-Mbeki | Adverse event frequencies are given without the denominator or the exposure period | Accepted |
| 15 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 7 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 4 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 2 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 2 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- Trials are described as terminated where they completed as planned — arising from DRAFT-TESAMORELIN-/002. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
- The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-TESAMORELIN-/003. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
- Regulatory status is stated without naming the jurisdiction — arising from DRAFT-TESAMORELIN-/005. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
- Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-TESAMORELIN-/006. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
- The mechanism section is written with more confidence than the clinical section it precedes — arising from DRAFT-TESAMORELIN-/007. Every pharmacology section now closes with a statement identifying which described actions are supported by clinical evidence assessed in §3 and which are not. The pharmacology itself is stated as the sources state it.
- The difference between pulsatile and continuous administration is not addressed — arising from DRAFT-TESAMORELIN-/008. The administration schedule is now stated with every effect estimate for these compounds, and the pharmacology section describes the dependence of direction on schedule.
- The search date is not on the face of the document — arising from DRAFT-TESAMORELIN-/010. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
- Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-TESAMORELIN-/011. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
- The analytical section assumes a reference standard that is not generally available — arising from DRAFT-TESAMORELIN-/013. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
- The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-TESAMORELIN-/014. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
- Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-TESAMORELIN-/015. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-080/3 · https://compoundevidence.com/comment-periods/draft-tesamorelin-monograph/disposition/ · retrieved 30 July 2026